Roivant flips ulcerative colitis drug to Roche for $7.1B, less than a year after getting the drug from Pfizer

Max Gelman

Senior Editor

Kyle LaHucik

Senior Reporter

Roivant will sell its potential blockbuster ulcerative colitis drug to Roche for $7.1 billion, less than a year after acquiring it from Pfizer for what …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roivant flips ulcerative colitis drug to Roche for $7.1B, less than a year after getting the drug from Pfizer

Max Gelman

Senior Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Roivant flips ul­cer­a­tive col­i­tis drug to Roche for $7.1B, less than a year af­ter get­ting the drug from Pfiz­er

Senior Editor

Senior Reporter

Sign up to read this article for free.

Roivant flips ulcerative colitis drug to Roche for $7.1B, less than a year after getting the drug from Pfizer